Clinical Trials Logo

Creutzfeldt-Jakob Syndrome clinical trials

View clinical trials related to Creutzfeldt-Jakob Syndrome.

Filter by:
  • None
  • Page 1

NCT ID: NCT05746715 Recruiting - Clinical trials for Creutzfeldt-Jakob Disease (CJD)

A Natural History Study of Preclinical Genetic Creutzfeldt-Jakob Disease (CJD)

NHS_CJD
Start date: June 1, 2022
Phase:
Study type: Observational

Creutzfeldt-Jakob Disease (CJD) is the most common prion disease in humans causing a rapidly progressive neurological decline and dementia and is invariably fatal. The familial forms (genetic CJD, gCJD) are caused by mutations in the PRNP gene encoding for the prion protein (PrP). In Israel, there is a large cluster of gCJD cases, carriers of an E200K mutation in the PRNP gene, and therefore the largest population of at-risk individuals in the world. The mutation is not necessarily sufficient for the formation and accumulation of the pathological prion protein (PrPsc), suggesting that other, genetic and non-genetic factors affect the age at symptoms onset. Here we present the protocol of a cross-sectional and longitudinal natural history study of gCJD patients and first-degree relatives of gCJD patients, aiming to identify biological markers of preclinical CJD and risk factors for phenoconversion. The study includes two groups: Patients diagnosed with gCJD, and first-degree healthy relatives (both carriers and non-carriers of the E200K mutation in the PRNP gene) of patients diagnosed with gCJD. At baseline, and at the end of every year (for 4 years), healthy participants are invited for an "in-depth" visit, which includes a clinical evaluation, blood and urine collection, gait assessment, brain MRI, lumbar puncture, and Polysomnography sleep lab (PSG). At 6 months from baseline, and then halfway through each year, participants are invited for a "brief" visit, which includes a clinical evaluation, short cognitive assessment, and blood and urine collection. gCJD patients will be invited for one "in-depth" visit, similar to the baseline visit of healthy relatives.

NCT ID: NCT05124392 Recruiting - Clinical trials for Familial Fatal Insomnia

Biomarker Profiling in Individuals at Risk for Prion Disease

Start date: December 1, 2017
Phase:
Study type: Observational [Patient Registry]

We are doing this research to identify biomarkers in individuals who are at-risk for familial prion disease. We hope to use these biomarkers to predict timing of disease onset in pre-symptomatic individuals and to guide the direction of future clinical trials.

NCT ID: NCT04944732 Completed - Clinical trials for Creutzfeldt Jakob Disease

Evaluation of Diagnostic Criteria for Creutzfeldt Jakob Disease

Start date: January 1, 2000
Phase:
Study type: Observational

Clinicians know little about Creutzfeldt Jakob disease, and they are not proficient in the diagnostic criteria of Creutzfeldt Jakob disease, so it is easy to misdiagnose or delay the diagnosis. As a rare central nervous system disease, it is necessary, feasible and practical to evaluate the diagnostic criteria of Creutzfeldt Jakob disease.

NCT ID: NCT02480725 Not yet recruiting - Clinical trials for Creutzfeldt-Jakob Syndrome

The Role of the Coagulation Pathway at the Synapse in Prion Diseases

Start date: June 2015
Phase: N/A
Study type: Observational

The study hypothesis is that that the deleterious effect of prions on the brain may be mediated (at least partially) by activation of serine proteases involved in the coagulation system. If this is true, then measurement of the activity of the coagulation system may be a marker of disease onset (in at higher risk individuals such as E200K* carriers) and for disease progression or activity in affected individuals. In addition, modulation of the coagulation system activity may be a potential tool for therapeutic intervention. *E200K- E200K mutation (Glu to Lys substitution) in the prion protein gene

NCT ID: NCT01050881 Completed - Hepatitis C Clinical Trials

Notification of Donors With Positive Microbiology Markers

Start date: March 2010
Phase:
Study type: Observational

Each year around 200 blood donors in the UK are found to be infected with blood-borne diseases (HIV, hepatitis B, hepatitis C, and HTLV), while several others have been identified as having an increased risk of variant Creutzfeldt-Jakob Disease (vCJD). Although the notification procedures for these infections vary, their effectiveness and appropriateness have never been evaluated in a systematic study. The proposed research has been designed to assess the responses of blood donors to notification and their satisfaction with how they were informed about the infection. The study will be implemented using standard questionnaire-based measures (French et al, 2004; Marteau & Bekker, 1992). The study will involve approximately 600 blood donors who were informed of an infection or possible infection with blood-borne diseases in 2008 and 2009, and approximately 100 donors notified of possible risk of vCJD infection in 2005. A comparable group of 2005 donors will be included to control for the effects of time. As the majority of donors testing positive donated to NHS Blood and Transplant (NHSBT), the participants will be identified from the NHSBT database only, and their availability confirmed through their GP or specialist clinician. A standardized questionnaire will be then sent to all those identified as eligible. The study will last 12 months, but direct participant involvement will be limited to the time required to complete the questionnaire, which should take under one hour. To safeguard confidentiality, no identifiable personal data will be used in the analysis. Where demographic or medical information already held by NHSBT is retrieved to minimise response burden, this will be pseudonymised before use. The study is sponsored by the blood services for England, Wales, Scotland and Northern Ireland. The results will be used to inform notification procedures in the future.

NCT ID: NCT00183092 Completed - Clinical trials for Creutzfeldt-Jakob Disease

CJD (Creutzfeldt-Jakob Disease) Quinacrine Study

Start date: April 2005
Phase: Phase 2
Study type: Interventional

The purpose of this clinical trial is to determine the effectiveness of the medication quinacrine on survival in sporadic Creutzfeldt-Jakob disease (sCJD).